drugset / Trial / NCT03648541
BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the long-term safety of BI 655130 (SPESOLIMAB) in patients with moderate to severely active ulcerative colitis, who have completed treatment in previous trials To evaluate the long-term efficacy of BI 655130 (SPESOLIMAB) in patients with moderate to severely active ulcerative colitis, who have completed treatment in previous trials
Timeline
- Start
- 2018-10-29
- Primary completion
- 2023-05-03
- Completion
- 2023-05-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Spesolimab | Monoclonal antibody | — | Intravenous |